Concepts (84)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Reactive | 1 | 2017 | 5 | 0.550 |
Why?
|
| Antitubercular Agents | 1 | 2017 | 263 | 0.460 |
Why?
|
| Syncope | 1 | 2015 | 54 | 0.450 |
Why?
|
| Defibrillators, Implantable | 1 | 2015 | 198 | 0.390 |
Why?
|
| Myocardial Ischemia | 1 | 2015 | 365 | 0.370 |
Why?
|
| Tuberculosis | 1 | 2017 | 554 | 0.350 |
Why?
|
| Tertiary Healthcare | 1 | 2009 | 20 | 0.320 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2009 | 184 | 0.290 |
Why?
|
| Virus Diseases | 2 | 2020 | 289 | 0.260 |
Why?
|
| Patient Care Management | 1 | 2020 | 68 | 0.170 |
Why?
|
| Pneumonia, Bacterial | 1 | 2020 | 81 | 0.160 |
Why?
|
| Coinfection | 1 | 2020 | 182 | 0.150 |
Why?
|
| Butyrates | 1 | 2018 | 42 | 0.140 |
Why?
|
| Bacteria | 2 | 2020 | 534 | 0.140 |
Why?
|
| Radiation Exposure | 1 | 2018 | 49 | 0.140 |
Why?
|
| Tuberculin Test | 1 | 2017 | 123 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 293 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 388 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 399 | 0.120 |
Why?
|
| Equipment Failure | 1 | 2015 | 133 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2018 | 538 | 0.110 |
Why?
|
| Dexamethasone | 1 | 2015 | 284 | 0.100 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 406 | 0.100 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2015 | 365 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1195 | 0.100 |
Why?
|
| Nocardia asteroides | 1 | 2012 | 2 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 708 | 0.100 |
Why?
|
| Nocardia | 1 | 2012 | 8 | 0.100 |
Why?
|
| Nocardia Infections | 1 | 2012 | 14 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 2519 | 0.090 |
Why?
|
| Visual Fields | 1 | 2011 | 151 | 0.080 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 822 | 0.080 |
Why?
|
| Macular Edema | 1 | 2011 | 99 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 1189 | 0.080 |
Why?
|
| Cytokines | 1 | 2015 | 1396 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2196 | 0.080 |
Why?
|
| Diabetic Retinopathy | 1 | 2011 | 169 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2012 | 401 | 0.070 |
Why?
|
| Retina | 1 | 2011 | 503 | 0.070 |
Why?
|
| Inflammation | 1 | 2015 | 1599 | 0.070 |
Why?
|
| Male | 7 | 2018 | 65904 | 0.060 |
Why?
|
| Visual Acuity | 1 | 2011 | 869 | 0.060 |
Why?
|
| Adult | 5 | 2018 | 31950 | 0.060 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2009 | 295 | 0.060 |
Why?
|
| Middle Aged | 5 | 2018 | 29409 | 0.060 |
Why?
|
| Humans | 9 | 2020 | 133935 | 0.060 |
Why?
|
| Hospital Mortality | 1 | 2009 | 1088 | 0.050 |
Why?
|
| Pakistan | 2 | 2015 | 94 | 0.050 |
Why?
|
| Heart Defects, Congenital | 1 | 2015 | 1874 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 1100 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2017 | 13010 | 0.040 |
Why?
|
| Female | 6 | 2018 | 71684 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 151 | 0.040 |
Why?
|
| Community-Acquired Infections | 1 | 2020 | 247 | 0.040 |
Why?
|
| APACHE | 1 | 2018 | 57 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 92 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2018 | 145 | 0.030 |
Why?
|
| Cross Infection | 1 | 2020 | 332 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2018 | 693 | 0.030 |
Why?
|
| Radiography | 1 | 2018 | 826 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 1976 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 163 | 0.030 |
Why?
|
| Feces | 1 | 2018 | 785 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1908 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 1382 | 0.020 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2012 | 40 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2012 | 105 | 0.020 |
Why?
|
| Fixation, Ocular | 1 | 2011 | 17 | 0.020 |
Why?
|
| Visual Field Tests | 1 | 2011 | 55 | 0.020 |
Why?
|
| Aged | 3 | 2018 | 21745 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2015 | 1667 | 0.020 |
Why?
|
| Risk Factors | 2 | 2018 | 11100 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2012 | 305 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2018 | 17487 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 1484 | 0.020 |
Why?
|
| Tomography, Optical Coherence | 1 | 2011 | 586 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 3426 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2012 | 5183 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 6663 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 7211 | 0.010 |
Why?
|
| Infant | 1 | 2015 | 13163 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2015 | 14802 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 20536 | 0.010 |
Why?
|
| Child | 1 | 2015 | 25742 | 0.010 |
Why?
|